Holen Sie sich die Stockscreener-App
67.87
0.73%
-0.50
Handel nachbörslich:
67.87
Schlusskurs vom Vortag:
$68.37
Offen:
$68.08
24-Stunden-Volumen:
731.94K
Relative Volume:
0.86
Marktkapitalisierung:
$3.18B
Einnahmen:
$1.35B
Nettoeinkommen (Verlust:
$163.34M
KGV:
20.72
EPS:
3.2763
Netto-Cashflow:
$189.17M
1W Leistung:
-3.18%
1M Leistung:
-15.46%
6M Leistung:
-9.75%
1J Leistung:
-4.80%
1-Tages-Spanne:
$67.63
$68.56
1-Wochen-Bereich:
$67.63
$73.00
52-Wochen-Spanne:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Firmenname
Haemonetics Corp
Sektor
Branche
Telefon
(781) 848-7100
Adresse
125 SUMMER STREET, BOSTON, MA
Vergleichen Sie HAE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
67.87 | 3.20B | 1.35B | 163.34M | 189.17M | 3.2763 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Herabstufung | Needham | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Bestätigt | Barrington Research | Outperform |
| 2025-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-06-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-02-07 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Eingeleitet | CL King | Buy |
| 2024-09-11 | Eingeleitet | BofA Securities | Neutral |
| 2024-09-10 | Eingeleitet | BTIG Research | Buy |
| 2024-06-12 | Hochstufung | Needham | Hold → Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-01-27 | Herabstufung | Needham | Buy → Hold |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Fortgesetzt | Raymond James | Outperform |
| 2021-06-17 | Eingeleitet | Citigroup | Buy |
| 2021-05-14 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Eingeleitet | Needham | Buy |
| 2019-08-07 | Bestätigt | Barrington Research | Outperform |
| 2019-05-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Bestätigt | Barrington Research | Outperform |
| 2018-08-09 | Bestätigt | Barrington Research | Outperform |
| 2018-02-07 | Bestätigt | Barrington Research | Outperform |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Bestätigt | Barrington Research | Outperform |
| 2017-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Bestätigt | The Benchmark Company | Hold |
| 2016-09-20 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-08-02 | Bestätigt | Jefferies | Buy |
| 2016-08-02 | Bestätigt | The Benchmark Company | Hold |
Alle ansehen
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Haemonetics Corporation $HAE Shares Sold by Riverwater Partners LLC - MarketBeat
Is Haemonetics (HAE) Offering Value After Prolonged Share Price Weakness - simplywall.st
Haemonetics Corporation (NYSE:HAE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Strong Results Lifted Haemonetics Corporation (HAE) in Q4 - Insider Monkey
Autotransfusion System Market is expected to reach US$ 1,094.30 - openPR.com
Balancing Plasma Strength Against Vascular Closure Uncertainty: Maintaining a Neutral (Hold) View on Haemonetics - TipRanks
Mizuho Markets Americas LLC Has $6.45 Million Stake in Haemonetics Corporation $HAE - MarketBeat
Schwartz Investment Counsel Inc. Has $6.69 Million Stock Holdings in Haemonetics Corporation $HAE - MarketBeat
BofA Securities Maintains Haemonetics(HAE.US) With Hold Rating, Maintains Target Price $90 - 富途资讯
Is Haemonetics (HAE) Offering An Opportunity After Recent Share Price Weakness - Yahoo Finance
Haemonetics (NYSE:HAE) Shares Gap DownHere's What Happened - MarketBeat
Is it Apt to Retain HAE Stock in Your Portfolio for Now? - Yahoo Finance
Will Haemonetics (HAE) beat estimates again in its next earnings report? - MSN
Orchestra BioMed to pick up $21M through Haemonetics’ acquisition of Vivasure - MassDevice
Barrington Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $93 - 富途资讯
Haemonetics (NYSE:HAE) Stock Price Down 6.2%Here's What Happened - MarketBeat
Haemonetics Corp (HAE) Trading Down 3.8% on Jan 13 - GuruFocus
A Look At Haemonetics (HAE) Valuation After Recent Share Price Strength And Margin Expansion Targets - simplywall.st
Haemonetics price target raised to $93 from $90 at Barrington - Yahoo Finance
Haemonetics Acquires Vivasure—Could This Be Its Next Growth Engine? - Smartkarma
Galway’s Vivasure Medical acquired by Haemonetics in €185m deal - Silicon Republic
Haemonetics (HAE) Acquisition of Vivasure Boosts Orchestra BioMed's Finances - GuruFocus
EQT To Sell Stake In Irish Biz To Haemonetics In €185M Deal - Law360
Here's Why Haemonetics (HAE) is a Strong Growth Stock - Yahoo Finance
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics - The Manila Times
HAE: Barrington Research Raises Price Target, Maintains Outperfo - GuruFocus
Where Haemonetics Stands With Analysts - Benzinga
Early bet on vessel-closure patch could bring this firm $21M windfall - Stock Titan
Barrington Research Forecasts Strong Price Appreciation for Haemonetics (NYSE:HAE) Stock - MarketBeat
Ireland: Haemonetics Corporation acquires Vivasure Medical for up to €185m - Investors in Healthcare
Haemonetics acquires Ireland-based Vivasure - Medical Device Network
EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics - Yahoo Finance
EQT Life Sciences Sells Vivasure Medical to Haemonetics - marketscreener.com
How Recent Moves Are Rewriting The Haemonetics (HAE) Story On Guidance And Valuation - Yahoo Finance
Haemonetics: Re-Rating Complete, Time To Cash In (NYSE:HAE) - Seeking Alpha
A Look At Haemonetics (HAE) Valuation After Recent Share Price Momentum - Yahoo Finance
Haemonetics (NYSE:HAE) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Haemonetics completes €185M Vivasure acquisition - BioWorld MedTech
Haemonetics to acquire Vivasure Medical - MedTech Dive
Haemonetics acquires Vivasure Medical for EUR 100M - TipRanks
Irish medtech Vivasure sold in €185m deal to US-listed Haemonetics - Business Post
Haemonetics (NYSE:HAE) Given Buy Rating at BTIG Research - MarketBeat
BTIG Reiterates Buy Rating for Haemonetics (HAE) at $88 Price Ta - GuruFocus
Haemonetics Expands Heart Surgery Arsenal With Vivasure Acquisition - Benzinga
Irish maker of dissolving vessel-closure implant sold in €185M deal - Stock Titan
Haemonetics (HAE) Acquires Vivasure Medical for €100M - GuruFocus
Haemonetics acquires Vivasure to expand structural heart portfolio - TipRanks
Haemonetics Acquires Vivasure Medical - Nasdaq
Haemonetics Corp Acquires Vivasure Medical Limited - TradingView
Haemonetics Acquires Vivasure Medical Limited - PR Newswire
Why Haemonetics Corporation stock is considered a top pick2025 Trading Recap & Fast Entry High Yield Tips - Улправда
Finanzdaten der Haemonetics Corp-Aktie (HAE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):